低泛免疫炎症值与免疫抑制状态脓毒症患者死亡率升高相关:一项多中心回顾性队列研究
该多中心回顾性队列研究基于MIMIC-IV数据库纳入1,898例免疫抑制状态脓毒症患者,按基线PIV三分位分为低、中、高三组。主要终点为院内全因死亡,次要终点包括1年全因死亡和ICU期间侵袭性真菌感染(IFI)。多因素调整后,低PIV(而非高PIV)与院内死亡(HR=1.42,95%CI 1.09-1.86,P=0.010)和1年死亡(HR=1.28,95%CI 1.06-1.53,P=0.009)独立相关;低PIV还与IFI风险升高相关(OR=1.46,95%CI 1.01-2.13,P=0.040)。中介分析提示IFI可能参与低PIV与死亡的关联,外部验证队列结果一致。
要点
- 在免疫抑制状态脓毒症患者中,低PIV组较中PIV组院内死亡和1年死亡显著升高。
- 多因素调整后,低PIV与院内死亡独立相关(HR=1.42,95%CI 1.09-1.86,P=0.010)。
- 低PIV与1年死亡独立相关(HR=1.28,95%CI 1.06-1.53,P=0.009)。
- 低PIV与ICU期间侵袭性真菌感染风险升高相关(OR=1.46,95%CI 1.01-2.13,P=0.040)。
- 中介分析提示IFI可能参与低PIV与死亡的关联,外部验证队列结果一致。
适用人群与场景
- 免疫抑制状态(ICS)的脓毒症患者,来源于MIMIC-IV数据库及一个独立外部验证队列。
诊断标准与关键阈值
- 根据基线PIV水平的三分位数将患者分为低、中、高PIV组。
- 原文未提及PIV的具体计算公式或阈值。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心回顾性队列研究,样本量1,898例,使用MIMIC-IV数据库及一个独立外部验证队列。
- 人群:免疫抑制状态的脓毒症患者,按基线PIV三分位分组。
- 主要终点:院内全因死亡;低PIV vs 中PIV的HR=1.42(95%CI 1.09-1.86,P=0.010)。
- 关键次要终点:1年全因死亡,低PIV vs 中PIV的HR=1.28(95%CI 1.06-1.53,P=0.009);ICU期间IFI,低PIV vs 中PIV的OR=1.46(95%CI 1.01-2.13,P=0.040)。
- 中介分析提示IFI可能参与低PIV与死亡的关联;外部验证队列中低PIV与死亡的关联一致。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究。
- 局限:回顾性设计,原文未提及具体证据等级;使用MIMIC-IV数据库可能存在选择偏倚;中介分析仅提示可能关联,需前瞻性验证。
对床旁实践的改变
- 在免疫抑制状态脓毒症患者中,低PIV而非高PIV提示院内及1年死亡风险升高,可考虑用于风险分层。
- 低PIV患者需警惕侵袭性真菌感染风险,原文提示IFI可能参与低PIV与死亡的关联。
- 原文未提及基于PIV的具体治疗干预或阈值调整,不能据此改变临床处置。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pan-immune-inflammation value (PIV) is a readily available biomarker reflecting systemic inflammatory and immune status. Although elevated PIV is generally associated with adverse outcomes, its prognostic significance in septic patients with immunocompromised status (ICS) remains unclear.
OBJECTIVE: To investigate the association between PIV and mortality in septic patients with ICS.
METHODS: Septic patients with ICS were identified from the MIMIC-IV database and stratified into low-, medium-, and high-PIV groups according to tertiles of baseline PIV levels. The primary outcome was in-hospital all-cause mortality, and secondary outcomes included 1-year all-cause mortality and invasive fungal infection (IFI) during ICU stay. Kaplan-Meier analysis, multivariable Cox regression, and logistic regression were used to assess the associations between PIV and clinical outcomes. Mediation analysis was performed to assess whether IFI might be involved in the association between PIV and mortality. An independent external cohort was used for validation.
RESULTS: A total of 1,898 patients with ICS were included. Compared with the medium-PIV group, the low-PIV group had significantly higher in-hospital and 1-year mortality. After multivariable adjustment, low PIV, rather than high PIV, was independently associated with increased in-hospital mortality (HR = 1.42, 95% CI: 1.09-1.86, P = 0.010) and 1-year mortality (HR = 1.28, 95% CI: 1.06-1.53, P = 0.009). Low PIV was also associated with increased odds of IFI in the MIMIC-IV cohort (OR = 1.46, 95% CI: 1.01-2.13, P = 0.040). Mediation analysis suggested a possible involvement of IFI in the association between low PIV and mortality in the MIMIC-IV cohort. In the external validation cohort, the association between low PIV and mortality was consistent.
CONCLUSION: In septic patients with ICS, low PIV, rather than high PIV, was independently associated with increased in-hospital and 1-year mortality. PIV may serve as a readily available biomarker for mortality risk stratification in this high-risk population.
参考来源
- Zhao Q, Ji X, Wei S, et al. Low pan-immune-inflammation value is associated with increased mortality in septic patients with immunocompromised status: a multicenter retrospective cohort study. Shock. 2026. PMID: 42517318. doi:10.1097/SHK.0000000000002914
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。